Sionna Therapeutics Inc. (SION)
NASDAQ: SIONHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 4.66 -3.37%
SION stock chart
Technical analysisKey statistics
All statistics- Market cap
- $217.62M
- EPS (TTM)
- -$2.16
- Dividend yield
- None
- 52-week range
- 4.01 – 54.97
- Day range
- 4.61 – 4.86
- Volume / Avg
- 879.93K / 2.19M
- Beta
- —
- Shares outstanding
- 45.15M
- Next earnings
- Nov 4, 2026
52-week range
SION stock today
Shares of Sionna Therapeutics (SION) finished higher on Oct 7 at $4.82, a gain of 1.47% or $0.07 per share, versus the S&P 500's 0.22% decline. Trading was light, with 879.93K shares changing hands, about 40% of the average daily volume. Shares are 91.2% below their 52-week high of $54.97, set on Aug 7, 2026 and 20.2% above the 52-week low of $4.01, near the bottom of the past year's range.
SION is down 88.3% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 83.2%. Sionna Therapeutics has posted a net loss over the last twelve months (EPS of -$2.16), so its P/E ratio is not meaningful. Sionna Therapeutics's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Sionna Therapeutics
Company profileSionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Michael Cloonan M.B.A.
- Headquarters
- Waltham, MA
- Employees
- 59
- IPO year
- 2025
- Website
- sionnatx.com
Analyst forecast
ForecastConsensus (12 analysts)
hold
Avg. price target
$21.00+335.68%
- Strong buy 0
- Buy 2
- Hold 10
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-0.62
Sionna Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TRDAEntrada Therapeutics Inc. | 5.61 | +3.51% | $218.43M | vs SION |
| LYELLyell Immunopharma Inc. | 8.56 | -0.58% | $209.76M | vs SION |
| NATRNature's Sunshine Products Inc. | 12.59 | +0.40% | $221.53M | vs SION |
| KROSKeros Therapeutics Inc. | 11.21 | +1.82% | $222.26M | vs SION |
| EVMNEvommune Inc. | 6.22 | -5.90% | $225.74M | vs SION |
| GLSIGreenwich LifeSciences Inc. | 15.39 | -2.53% | $225.90M | vs SION |
| MGNXMacroGenics Inc. | 3.55 | -2.47% | $226.14M | vs SION |
| RNACCartesian Therapeutics Inc. | 6.68 | -1.04% | $202.11M | vs SION |
Indexes, lists and sector
Sionna Therapeutics stock FAQ
What is Sionna Therapeutics's stock price today?
SION last traded at $4.82 as of Oct 7, 4:00 PM EDT, up 1.47% on the day. Prices are delayed at least 15 minutes.
When is Sionna Therapeutics's next earnings date?
Sionna Therapeutics is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-0.62.
Who is Sionna Therapeutics's CEO?
Mr. Michael Cloonan M.B.A. is the chief executive officer of Sionna Therapeutics Inc., which has about 59 employees.
What is the SION 52-week high?
The 52-week high for SION is $54.97 and the 52-week low is $4.01. The stock is currently 91.2% below its high.